We are live on ! Find out more
FENC icon

Fennec Pharmaceuticals
FENC

64 hedge funds and large institutions have $87.7M invested in Fennec Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 26 increasing their positions, 11 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

136% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 11

0% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 17

1.02% less ownership

Funds ownership: 53.58% → 52.56% (-1%)

2% less funds holding

Funds holding: 65 → 64 (-1)

46% less capital invested

Capital invested by funds: $161M → $87.7M (-$73.4M)

60% less funds holding in top 10

Funds holding in top 10: 5 → 2 (-3)

94% less call options, than puts

Call options by funds: $1K | Put options by funds: $18K

Holders
64
Holders Change
-1
Holders Change %
-1.54%
% of All Funds
0.92%
Holding in Top 10
2
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-60%
% of All Funds
0.03%
New
17
Increased
26
Reduced
11
Closed
17
Calls
$1K
Puts
$18K
Net Calls
-$17K
Net Calls Change
-$508K

Top Buyers

1
BlackRock
BlackRock
New York
+$2.16M
2
SCM
Solas Capital Management
Connecticut
+$1.91M
3
DCM
DG Capital Management
New York
+$1.02M
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$680K
5
WG
Winton Group
United Kingdom
+$556K

Top Sellers

1
ACM
AIGH Capital Management
Maryland
-$6.34M
2
EIM
Essex Investment Management
Massachusetts
-$1.6M
3
Renaissance Technologies
Renaissance Technologies
New York
-$1.56M
4
LCM
Legato Capital Management
California
-$635K
5
Citadel Advisors
Citadel Advisors
Florida
-$542K
Name Holding Trade Value Shares
Change 		Change in
Stake
SCA
1
Southpoint Capital Advisors
New York
$24.9M – – –
SGL
2
Sonic GP LLC
Hawaii
$14.7M – – –
DCM
3
DG Capital Management
New York
$9.99M +$1.02M +123,148 +8%
SCM
4
Solas Capital Management
Connecticut
$8.19M +$1.91M +229,767 +21%
BlackRock
5
BlackRock
New York
$7.25M +$2.16M +259,776 +28%
Vanguard Group
6
Vanguard Group
Pennsylvania
$6.27M +$108K +13,028 +1%
HFA
7
Harbert Fund Advisors
Alabama
$2.85M – – –
State Street
8
State Street
Massachusetts
$1.96M +$147K +17,687 +6%
Geode Capital Management
9
Geode Capital Management
Massachusetts
$1.84M +$680K +81,824 +37%
GJL
10
Gendell Jeffrey L
$1.73M -$159K -19,113 -6%
LPC
11
Lion Point Capital
New York
$1.04M – – –
Northern Trust
12
Northern Trust
Illinois
$650K -$63.7K -7,669 -7%
Morgan Stanley
13
Morgan Stanley
New York
$624K +$232K +27,995 +38%
Millennium Management
14
Millennium Management
New York
$424K +$89.7K +10,800 +18%
Bank of New York Mellon
15
Bank of New York Mellon
New York
$420K +$171K +20,602 +43%
WG
16
Winton Group
United Kingdom
$409K +$556K +67,005 New
CIBC World Market
17
CIBC World Market
Ontario, Canada
$348K -$109K -13,180 -19%
Charles Schwab
18
Charles Schwab
California
$339K +$116K +13,955 +34%
Russell Investments Group
19
Russell Investments Group
United Kingdom
$326K +$158K +19,049 +56%
HFM
20
Hartford Financial Management
Connecticut
$298K +$8.72K +1,050 +2%
Qube Research & Technologies (QRT)
21
Qube Research & Technologies (QRT)
United Kingdom
$287K +$316K +38,100 +429%
BNP Paribas Financial Markets
22
BNP Paribas Financial Markets
France
$287K +$117K +14,141 +43%
Verition Fund Management
23
Verition Fund Management
Connecticut
$206K +$280K +33,738 New
RhumbLine Advisers
24
RhumbLine Advisers
Massachusetts
$178K +$74.6K +8,987 +45%
SPA
25
Sherbrooke Park Advisers
New York
$173K +$236K +28,370 New
1
2 3 4

FENC Hedge Fund Activity: Q2 2024 in Review

64 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Fennec Pharmaceuticals (FENC) for Q2 2024, worth a combined $87.7M — down 46% from $161M a quarter earlier.

Fund positioning in FENC was balanced in Q2 2024: 17 funds opened new positions, 17 closed out, 26 added to existing stakes and 11 trimmed.

The largest buyer was BlackRock, adding an estimated $2.16M. The largest seller was AIGH Capital Management, exiting entirely with an estimated $6.34M sold.

  • 64 institutional investors held Fennec Pharmaceuticals (FENC) as of Q2 2024, down from 65 in Q1 2024.
  • Funds reported $87.7M of Fennec Pharmaceuticals stock for Q2 2024, down 46% quarter-over-quarter.
  • 17 funds opened new Fennec Pharmaceuticals positions in Q2 2024 and 17 closed out, a net change of 0 holders.
  • The largest Fennec Pharmaceuticals buyer in Q2 2024 was BlackRock, an estimated $2.16M added.
  • The largest Fennec Pharmaceuticals seller in Q2 2024 was AIGH Capital Management, an estimated $6.34M sold.

Based on aggregated 13F filings for Q2 2024.